Transdermal delivery system for the administration of rotigotine
DC CAFCFirst Claim
Patent Images
1. A transdermal delivery system (TDS) comprising a self-adhesive matrix of a thickness and a backing layer,wherein the self-adhesive matrix comprises (1) a solid or semi-solid semi-permeable polymer matrix and (2) microreservoirs comprising rotigotine as free base;
- wherein the polymer matrix comprises up to about 10% w/w of protonated rotigotine;
wherein the polymer matrix is permeable to unprotonated rotigotine and substantially impermeable to protonated rotigotine; and
wherein the microreservoirs have a maximum diameter up to 70% of the thickness of the self-adhesive matrix.
2 Assignments
Litigations
0 Petitions
Accused Products
Abstract
An improved Transdermal Delivery System (TDS) comprising a backing layer inert to the components of the matrix, a self-adhesive matrix containing rotigotine and a protective foil or sheet to be removed prior to use,
characterized in that
the self-adhesive matrix consists of a solid or semi-solid semi-permeable polymer
-
- (1) wherein rotigotine in its free base form has been incorporated,
- (2) which is saturated with rotigotine and contains said rotigotine as a multitude of microreservoirs within the matrix,
- (3) which is highly permeable for the free base of rotigotine,
- (4) which is impermeable for the protonated form of rotigotine,
- (5) wherein the maximum diameter of the microreservoirs is less than the thickness of the matrix.
is provided. Said TDS provides for enhanced flux of rotigotine across the TDS/skin interface.
129 Citations
30 Claims
-
1. A transdermal delivery system (TDS) comprising a self-adhesive matrix of a thickness and a backing layer,
wherein the self-adhesive matrix comprises (1) a solid or semi-solid semi-permeable polymer matrix and (2) microreservoirs comprising rotigotine as free base; -
wherein the polymer matrix comprises up to about 10% w/w of protonated rotigotine; wherein the polymer matrix is permeable to unprotonated rotigotine and substantially impermeable to protonated rotigotine; and wherein the microreservoirs have a maximum diameter up to 70% of the thickness of the self-adhesive matrix. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 27, 28)
-
-
15. A transdermal delivery system (TDS) comprising a self-adhesive matrix of a thickness and a backing layer,
wherein the self-adhesive matrix comprises (1) a solid or semi-solid semi-permeable polymer matrix and (2) microreservoirs comprising rotigotine as free base; -
wherein the polymer matrix comprises up to about 10% w/w of protonated rotigotine; wherein the polymer matrix is permeable to unprotonated rotigotine and substantially impermeable to protonated rotigotine; and wherein the microreservoirs have a mean diameter in the range of 1% to 40% of the thickness of the self-adhesive matrix. - View Dependent Claims (16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 29, 30)
-
Specification